View Financial HealthElite Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6Elite Pharmaceuticals 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.07%자사주 매입 수익률총 주주 수익률-0.07%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • 7hElite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc. reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug product. IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million. The studies conducted were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two-sequence, crossover bioequivalence studies in normal, healthy, adult, human subjects under fasting conditions. The results indicated that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.공시 • Feb 12Elite Pharmaceuticals, Inc. to Report Q3, 2026 Results on Feb 17, 2026Elite Pharmaceuticals, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 17, 2026공시 • Nov 10Elite Pharmaceuticals, Inc. to Report Q2, 2026 Results on Nov 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q2, 2026 results on Nov 14, 2025공시 • Aug 09Elite Pharmaceuticals, Inc. to Report Q1, 2026 Results on Aug 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q1, 2026 results on Aug 14, 2025공시 • Jun 23Elite Pharmaceuticals, Inc. to Report Fiscal Year 2025 Results on Jun 30, 2025Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2025 results on Jun 30, 2025공시 • Nov 11Elite Pharmaceuticals, Inc. to Report Q2, 2025 Results on Nov 14, 2024Elite Pharmaceuticals, Inc. announced that they will report Q2, 2025 results on Nov 14, 2024공시 • Jun 27Elite Pharmaceuticals, Inc. to Report Q4, 2024 Results on Jul 01, 2024Elite Pharmaceuticals, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Jul 01, 2024공시 • May 23Elite Pharmaceuticals Receives Fda Approval for Generic MethotrexateElite Pharmaceuticals, Inc. announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label. IQVIA reported annual sales of $64.3 million for the twelve months ending March 2024 for the generic market for this product.공시 • Feb 09Elite Pharmaceuticals, Inc. to Report Q3, 2024 Results on Feb 14, 2024Elite Pharmaceuticals, Inc. announced that they will report Q3, 2024 results on Feb 14, 2024공시 • Dec 26Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System StimulantElite Pharmaceuticals, Inc. announced the US Food and Drug Administration's (FDA) acceptance for review of an Abbreviated New Drug Application (ANDA) on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.공시 • Nov 11Elite Pharmaceuticals, Inc. to Report Q2, 2024 Results on Nov 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Nov 14, 2023공시 • Sep 26Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic ProductElite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics. IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product.공시 • Sep 08Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial OfficerElite Pharmaceuticals, Inc. announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023. Mr. Ward previously served as the Company's Chief Financial Officer from July 2009 through May 2021, and the Company is pleased to have Mr. Ward join the company again as CFO. Mr. Ward has over 30 years of industry experience, most recently as chief financial officer of Mirror Biologics, Inc., a privately held life science company and before that as chief financial officer of Enveric Biosciences, Inc., a publicly traded biotech company. Prior to Mr. Ward's initial tenure with the Company, Mr. Ward filled multiple finance and supply chain leadership roles with the Actavis Group and its U.S. subsidiary, Amide Pharmaceutical, Inc. and was also a consultant for Centennial Communications Corp., a Nasdaq-listed wireless communications provider where he was engaged in improving internal controls and supporting Sarbanes-Oxley compliance. Mr. Ward began his career as a certified public accountant in the audit department of KPMG and holds a Bachelor of Science degree in accounting from Long Island University in Brooklyn, N.Y, graduating summa cum laude.공시 • Aug 29Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc. engaged in the development, manufacture, and distribution of niche generic products, reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called CNS stimulants. IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product. The studies were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two sequence, two-way crossover comparative bioavailability studies in healthy, adult, human subjects under fed and fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.공시 • Aug 10Elite Pharmaceuticals, Inc. to Report Q1, 2024 Results on Aug 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q1, 2024 results on Aug 14, 2023공시 • Jun 23Elite Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Jun 29, 2023Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Jun 29, 2023공시 • May 04Elite Pharmaceuticals, Inc Appoints Mark Pellegrino as its Chief Financial OfficerElite Pharmaceuticals, Inc. announced the appointment of Mark Pellegrino as its Chief Financial Officer (CFO), effective May 1, 2023. Pellegrino joins Elite with more than 30 years of experience in financial and operational leadership, primarily in the life sciences sector, including manufacturing and distribution. Pellegrino served for nearly a decade as Senior Director of Finance and Administration at Kedrion Biopharma, Inc., the U.S. division of a multi-national company. Pellegrino also served as CFO for Digital Products, Inc. and spent fifteen years as Vice President of Finance for Romaco, Inc. He most recently held a position at Barbera & Barbera as a consultant in finance and tax. Pellegrino brings a wealth of diversified leadership in corporate operations, corporate finance, and accounting for private and public companies.공시 • Feb 09Elite Pharmaceuticals, Inc. to Report Q3, 2023 Results on Feb 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Feb 14, 2023공시 • Feb 08Elite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc. reported positive results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites . IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product. The studies were open label, single-dose crossover comparative bioavailability studies in volunteers of male and female patients who were already on established drug regimens under fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.공시 • Nov 09Elite Pharmaceuticals, Inc. to Report Q2, 2023 Results on Nov 14, 2022Elite Pharmaceuticals, Inc. announced that they will report Q2, 2023 results on Nov 14, 2022공시 • Sep 08Elite Pharmaceuticals, Inc. Appoints Kirko Kirkov as Chief Commercial OfficerOn September 5, 2022, Elite Pharmaceuticals, Inc. entered into an employment agreement with Kirko Kirkov to serve as the Registrants’ Chief Commercial Officer effective September 6, 2022. Mr. Kirkov joins Elite as an accomplished and multi-faceted leader with more than twenty years of in-depth business development skills across international pharmaceutical organizations. Before joining the Registrant, Mr. Kirkov served as General Manager of Vertice Pharma, a specialty generics pharmaceutical company, from February 2020 to present. From April 2008 to February 2020, Mr. Kirkov was employed by Sandoz and served in positions of increasing responsibilities beginning with Country Head & Managing Director of Bulgaria from 2008 to 2011. From 2011 to 2013, Mr. Kirkov served as Sandoz’s Business Unit Head, Branded Prescription Generics in Russia, and most recently, from January 2013 to February 2020, served as Sandoz’s Executive Director, Commercial Operations. Mr. Kirkov brings with him a broad range of experience in the areas of business development, operationalization of commercial strategy, and implementation of retail and wholesale channel sales operations, having overseen sales portfolios consisting of 400+ product families, and 1500+ SKUs covering both generic and branded products. Mr. Kirkov has a Bachelor of Science in Mechanical Engineering /Engineering Management from the University of Ottawa, two Masters of Science degrees respectively in Naval Architecture and Ocean Systems Management from the Massachusetts Institute of Technology, a Masters of Science in Applied Positive Psychology and Coaching from the University of East London, and an MBA from the University of Durham. Mr. Kirkov joins Elite in a newly created position to oversee the sale and marketing of commercial products not under license under Elite’s label.공시 • Aug 12Elite Pharmaceuticals, Inc. to Report Q1, 2023 Results on Aug 15, 2022Elite Pharmaceuticals, Inc. announced that they will report Q1, 2023 results on Aug 15, 2022공시 • Jun 24Elite Pharmaceuticals, Inc. to Report Fiscal Year 2022 Results on Jun 29, 2022Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2022 results on Jun 29, 2022공시 • May 12Elite Pharmaceuticals, Inc. Announces the Appointment of Robert Chen, CPA/MPA, as Chief Financial Officer, Effective May 16, 2022, Succeeding Marc BregmanElite Pharmaceuticals, Inc. announced the appointment of Robert Chen, CPA/MPA, as its Chief Financial Officer, effective May 16, 2022, succeeding Marc Bregman. Chen joins Elite with broad experience in financial and operational leadership for life science companies, both private and public, ranging from preclinical development to commercial operations. Mr. Chen brings with him extensive and diversified financial leadership background in the areas of financial reporting, including manufacturing, financial and cost accounting, SEC, GAAP and IFRS, as well as financial planning and analysis. Mr. Chen previously served in roles as CFO, Vice President of Finance, and Corporate Controller primarily in the life sciences sector. Mr. Chen most recently served as Vice President of Finance for KBP Biosciences, a clinical-stage biotech start-up. Mr. Chen also held financial positions with Bradley Pharmaceuticals, Novartis, Victory Commercial Management, Medimetriks Pharmaceuticals, and Taiho Oncology.공시 • Apr 19+ 1 more updateMarc Bregman Notifies Elite Pharmaceuticals, Inc. of His Intent to Leave and Resign from His Position as Chief Financial Officer, Treasurer and SecretaryOn April 14, 2022, Marc Bregman notified Elite Pharmaceuticals, Inc. of his intent to leave the Company and resign from his position as Chief Financial Officer, Treasurer and Secretary to pursue another opportunity. Mr. Bregman's last day with the Company will be April 29, 2022.공시 • Feb 10Elite Pharmaceuticals, Inc. to Report Q3, 2022 Results on Feb 14, 2022Elite Pharmaceuticals, Inc. announced that they will report Q3, 2022 results on Feb 14, 2022공시 • Feb 11Elite Pharmaceuticals, Inc. to Report Q3, 2021 Results on Feb 16, 2021Elite Pharmaceuticals, Inc. announced that they will report Q3, 2021 results on Feb 16, 2021공시 • Nov 12Elite Pharmaceuticals, Inc. to Report Q2, 2021 Results on Nov 16, 2020Elite Pharmaceuticals, Inc. announced that they will report Q2, 2021 results at 8:40 PM, GMT Standard Time on Nov 16, 2020공시 • Aug 13Elite Pharmaceuticals, Inc. to Report Q1, 2021 Results on Aug 14, 2020Elite Pharmaceuticals, Inc. announced that they will report Q1, 2021 results at 8:40 PM, GMT Standard Time on Aug 14, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ELTP 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ELTP 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Elite Pharmaceuticals 배당 수익률 vs 시장ELTP의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ELTP)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Pharmaceuticals)2.0%분석가 예측 (ELTP) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ELTP 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ELTP 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ELTP 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ELTP 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 07:38종가2026/06/17 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Elite Pharmaceuticals, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • 7hElite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc. reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug product. IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million. The studies conducted were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two-sequence, crossover bioequivalence studies in normal, healthy, adult, human subjects under fasting conditions. The results indicated that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.
공시 • Feb 12Elite Pharmaceuticals, Inc. to Report Q3, 2026 Results on Feb 17, 2026Elite Pharmaceuticals, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 17, 2026
공시 • Nov 10Elite Pharmaceuticals, Inc. to Report Q2, 2026 Results on Nov 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q2, 2026 results on Nov 14, 2025
공시 • Aug 09Elite Pharmaceuticals, Inc. to Report Q1, 2026 Results on Aug 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q1, 2026 results on Aug 14, 2025
공시 • Jun 23Elite Pharmaceuticals, Inc. to Report Fiscal Year 2025 Results on Jun 30, 2025Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2025 results on Jun 30, 2025
공시 • Nov 11Elite Pharmaceuticals, Inc. to Report Q2, 2025 Results on Nov 14, 2024Elite Pharmaceuticals, Inc. announced that they will report Q2, 2025 results on Nov 14, 2024
공시 • Jun 27Elite Pharmaceuticals, Inc. to Report Q4, 2024 Results on Jul 01, 2024Elite Pharmaceuticals, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Jul 01, 2024
공시 • May 23Elite Pharmaceuticals Receives Fda Approval for Generic MethotrexateElite Pharmaceuticals, Inc. announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label. IQVIA reported annual sales of $64.3 million for the twelve months ending March 2024 for the generic market for this product.
공시 • Feb 09Elite Pharmaceuticals, Inc. to Report Q3, 2024 Results on Feb 14, 2024Elite Pharmaceuticals, Inc. announced that they will report Q3, 2024 results on Feb 14, 2024
공시 • Dec 26Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System StimulantElite Pharmaceuticals, Inc. announced the US Food and Drug Administration's (FDA) acceptance for review of an Abbreviated New Drug Application (ANDA) on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.
공시 • Nov 11Elite Pharmaceuticals, Inc. to Report Q2, 2024 Results on Nov 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Nov 14, 2023
공시 • Sep 26Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic ProductElite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics. IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product.
공시 • Sep 08Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial OfficerElite Pharmaceuticals, Inc. announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023. Mr. Ward previously served as the Company's Chief Financial Officer from July 2009 through May 2021, and the Company is pleased to have Mr. Ward join the company again as CFO. Mr. Ward has over 30 years of industry experience, most recently as chief financial officer of Mirror Biologics, Inc., a privately held life science company and before that as chief financial officer of Enveric Biosciences, Inc., a publicly traded biotech company. Prior to Mr. Ward's initial tenure with the Company, Mr. Ward filled multiple finance and supply chain leadership roles with the Actavis Group and its U.S. subsidiary, Amide Pharmaceutical, Inc. and was also a consultant for Centennial Communications Corp., a Nasdaq-listed wireless communications provider where he was engaged in improving internal controls and supporting Sarbanes-Oxley compliance. Mr. Ward began his career as a certified public accountant in the audit department of KPMG and holds a Bachelor of Science degree in accounting from Long Island University in Brooklyn, N.Y, graduating summa cum laude.
공시 • Aug 29Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc. engaged in the development, manufacture, and distribution of niche generic products, reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called CNS stimulants. IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product. The studies were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two sequence, two-way crossover comparative bioavailability studies in healthy, adult, human subjects under fed and fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.
공시 • Aug 10Elite Pharmaceuticals, Inc. to Report Q1, 2024 Results on Aug 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q1, 2024 results on Aug 14, 2023
공시 • Jun 23Elite Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Jun 29, 2023Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Jun 29, 2023
공시 • May 04Elite Pharmaceuticals, Inc Appoints Mark Pellegrino as its Chief Financial OfficerElite Pharmaceuticals, Inc. announced the appointment of Mark Pellegrino as its Chief Financial Officer (CFO), effective May 1, 2023. Pellegrino joins Elite with more than 30 years of experience in financial and operational leadership, primarily in the life sciences sector, including manufacturing and distribution. Pellegrino served for nearly a decade as Senior Director of Finance and Administration at Kedrion Biopharma, Inc., the U.S. division of a multi-national company. Pellegrino also served as CFO for Digital Products, Inc. and spent fifteen years as Vice President of Finance for Romaco, Inc. He most recently held a position at Barbera & Barbera as a consultant in finance and tax. Pellegrino brings a wealth of diversified leadership in corporate operations, corporate finance, and accounting for private and public companies.
공시 • Feb 09Elite Pharmaceuticals, Inc. to Report Q3, 2023 Results on Feb 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Feb 14, 2023
공시 • Feb 08Elite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc. reported positive results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites . IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product. The studies were open label, single-dose crossover comparative bioavailability studies in volunteers of male and female patients who were already on established drug regimens under fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.
공시 • Nov 09Elite Pharmaceuticals, Inc. to Report Q2, 2023 Results on Nov 14, 2022Elite Pharmaceuticals, Inc. announced that they will report Q2, 2023 results on Nov 14, 2022
공시 • Sep 08Elite Pharmaceuticals, Inc. Appoints Kirko Kirkov as Chief Commercial OfficerOn September 5, 2022, Elite Pharmaceuticals, Inc. entered into an employment agreement with Kirko Kirkov to serve as the Registrants’ Chief Commercial Officer effective September 6, 2022. Mr. Kirkov joins Elite as an accomplished and multi-faceted leader with more than twenty years of in-depth business development skills across international pharmaceutical organizations. Before joining the Registrant, Mr. Kirkov served as General Manager of Vertice Pharma, a specialty generics pharmaceutical company, from February 2020 to present. From April 2008 to February 2020, Mr. Kirkov was employed by Sandoz and served in positions of increasing responsibilities beginning with Country Head & Managing Director of Bulgaria from 2008 to 2011. From 2011 to 2013, Mr. Kirkov served as Sandoz’s Business Unit Head, Branded Prescription Generics in Russia, and most recently, from January 2013 to February 2020, served as Sandoz’s Executive Director, Commercial Operations. Mr. Kirkov brings with him a broad range of experience in the areas of business development, operationalization of commercial strategy, and implementation of retail and wholesale channel sales operations, having overseen sales portfolios consisting of 400+ product families, and 1500+ SKUs covering both generic and branded products. Mr. Kirkov has a Bachelor of Science in Mechanical Engineering /Engineering Management from the University of Ottawa, two Masters of Science degrees respectively in Naval Architecture and Ocean Systems Management from the Massachusetts Institute of Technology, a Masters of Science in Applied Positive Psychology and Coaching from the University of East London, and an MBA from the University of Durham. Mr. Kirkov joins Elite in a newly created position to oversee the sale and marketing of commercial products not under license under Elite’s label.
공시 • Aug 12Elite Pharmaceuticals, Inc. to Report Q1, 2023 Results on Aug 15, 2022Elite Pharmaceuticals, Inc. announced that they will report Q1, 2023 results on Aug 15, 2022
공시 • Jun 24Elite Pharmaceuticals, Inc. to Report Fiscal Year 2022 Results on Jun 29, 2022Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2022 results on Jun 29, 2022
공시 • May 12Elite Pharmaceuticals, Inc. Announces the Appointment of Robert Chen, CPA/MPA, as Chief Financial Officer, Effective May 16, 2022, Succeeding Marc BregmanElite Pharmaceuticals, Inc. announced the appointment of Robert Chen, CPA/MPA, as its Chief Financial Officer, effective May 16, 2022, succeeding Marc Bregman. Chen joins Elite with broad experience in financial and operational leadership for life science companies, both private and public, ranging from preclinical development to commercial operations. Mr. Chen brings with him extensive and diversified financial leadership background in the areas of financial reporting, including manufacturing, financial and cost accounting, SEC, GAAP and IFRS, as well as financial planning and analysis. Mr. Chen previously served in roles as CFO, Vice President of Finance, and Corporate Controller primarily in the life sciences sector. Mr. Chen most recently served as Vice President of Finance for KBP Biosciences, a clinical-stage biotech start-up. Mr. Chen also held financial positions with Bradley Pharmaceuticals, Novartis, Victory Commercial Management, Medimetriks Pharmaceuticals, and Taiho Oncology.
공시 • Apr 19+ 1 more updateMarc Bregman Notifies Elite Pharmaceuticals, Inc. of His Intent to Leave and Resign from His Position as Chief Financial Officer, Treasurer and SecretaryOn April 14, 2022, Marc Bregman notified Elite Pharmaceuticals, Inc. of his intent to leave the Company and resign from his position as Chief Financial Officer, Treasurer and Secretary to pursue another opportunity. Mr. Bregman's last day with the Company will be April 29, 2022.
공시 • Feb 10Elite Pharmaceuticals, Inc. to Report Q3, 2022 Results on Feb 14, 2022Elite Pharmaceuticals, Inc. announced that they will report Q3, 2022 results on Feb 14, 2022
공시 • Feb 11Elite Pharmaceuticals, Inc. to Report Q3, 2021 Results on Feb 16, 2021Elite Pharmaceuticals, Inc. announced that they will report Q3, 2021 results on Feb 16, 2021
공시 • Nov 12Elite Pharmaceuticals, Inc. to Report Q2, 2021 Results on Nov 16, 2020Elite Pharmaceuticals, Inc. announced that they will report Q2, 2021 results at 8:40 PM, GMT Standard Time on Nov 16, 2020
공시 • Aug 13Elite Pharmaceuticals, Inc. to Report Q1, 2021 Results on Aug 14, 2020Elite Pharmaceuticals, Inc. announced that they will report Q1, 2021 results at 8:40 PM, GMT Standard Time on Aug 14, 2020